atai Life SciencesNASDAQ: ATAI

atai Life Sciences was a clinical-stage biopharmaceutical platform company founded in 2018 by entrepreneur Christian Angermayer and listed on NASDAQ. Operating as a portfolio model, atai held stakes in multiple subsidiary companies each pursuing distinct psychedelic compounds and psychiatric indications — including VLS-01 (buccal DMT film for TRD), EMP-01 (oral R-MDMA for social anxiety disorder), and RL-007 (cognitive impairment in schizophrenia, via Recognify Life Sciences). In November 2025, atai completed an all-share strategic merger with Beckley Psytech to form AtaiBeckley N.V., which subsequently redomiciled to Delaware as AtaiBeckley Inc. All active pipeline programmes were consolidated under AtaiBeckley.